Hyderabad: Following Medtronic’s recent announcement of establishing a Global Capability Center (GCC) in Hyderabad, Paris-based pharmaceutical and healthcare giant Sanofi revealed on Wednesday its plan to invest €400 million (approximately Rs 3,600 crore) in its Hyderabad GCC by 2030. Of this amount, €100 million (around Rs 900 crore) will be invested by 2025. Currently, the company employs about 1,000 people, with plans to increase this number to approximately 2,600 within two years, making Hyderabad the largest of Sanofi’s four global hubs.
Speaking at the inauguration of Sanofi Healthcare India’s expanded GCC facility at Hitec City, IT and Industries Minister D. Sridhar Babu stated, “The expansion of Sanofi’s GCC in Hyderabad signifies a significant advancement for Telangana’s rapidly growing role in the global pharmaceutical industry. This substantial investment of over €400 million and the creation of over 2,600 jobs in the next two years highlight Telangana’s dedication to fostering a thriving environment for innovation and growth.”
Similar to its other GCCs, Sanofi’s Hyderabad hub will serve as a strategic center, providing the company with a competitive advantage in delivering enterprise solutions. This key ‘nerve center’ will facilitate centralization and modernization, enabling scaling-up opportunities across Sanofi’s value chain. The hub will offer a range of services including commercial, manufacturing, supply, research and development, and digital.
Established in 2019, the Hyderabad hub has rapidly expanded from being a medical center to providing a range of services to Sanofi’s global functions and affiliates worldwide. “Hyderabad is becoming a preferred destination for shared services due to its large talent pool. We are excited to invest and develop this hub into a leading global community dedicated to excellence, with digitalization at the core of our transformation. This hub will drive Sanofi’s efficiency and revolutionize our operations as we pursue scientific breakthroughs to improve lives,” said Madeleine Roach, Executive Vice President of Business Operations at Sanofi. “Our goal is to become the first biopharma company powered by artificial intelligence (AI) at scale. From discovery to treatment, we are leveraging AI ethically and safely to expedite the market delivery of our drugs to address numerous unmet needs,” added Emmanuel Frenehard, Executive Vice President and Chief Digital Officer at Sanofi.
